Efficacy of Montelukast on STEMl Patients

Inclusion Criteria: 1. Age \> 18 years and \< 75 years; 2. Diagnosed with acute anterior ST-segment elevation myocardial infarction and planned to undergo primary percutaneous coronary intervention; 3. Time from symptom onset ≤ 12 hours; 4. The patient and their family members voluntarily participate in this study and sign the informed consent form. Exclusion Criteria: 1. Cardiogenic shock, severe heart failure (Killip Class IV), or structural complications such as papillary muscle rupture; 2. Having received cardiopulmonary resuscitation ; 3. Severe and inadequately controlled hypertension (systolic blood pressure \> 180 mmHg and/or diastolic blood pressure \> 110 mmHg); 4. Severe liver dysfunction (alanine aminotransferase (ALT) or aspartate aminotransferase (AST) exceeding three times the upper limit of normal) or renal dysfunction (estimated glomerular filtration rate (eGFR) \< 30 mL/min/1.73 m²); 5. History of myocardial infarction; 6. Concomitant active bleeding or visceral hemorrhage; 7. Concomitant malignant tumors, lymphomas, leukemias, or other diseases with an expected survival time of less than 1 year; 8. Having undergone gastrointestinal surgery within the past 4 weeks that may affect the absorption of the investigational drug; 9. Pregnant or breastfeeding women; 10. Family history of psychiatric disorders; 11. Having been enrolled in another drug study within the past 4 weeks or currently receiving any investigational treatment other than the study drug; 12. Allergic to montelukast or having used montelukast within the past 4 weeks; 13. Unable to tolerate cardiac magnetic resonance imaging (e.g., patients with magnetic materials in the body or those with claustrophobia).